evaluate the pharmacokinetics of bat2606 injection in healthy chinese male subjects

Conditions: Severe Asthma

Summary: to evaluate the pharmacokinetics, safety and immunogenicity of bat2606 in healthy china male subjects.

this is a single-center, randomized, double-blind, single-dose, parallel three arms comparative study of pharmacokinetics, safety and immunogenicity.

Eligibility criteria:
inclusion criteria: * 1. subjects have signed the informed consent before the trial, and fully understood the content, process and relevant risks of the trial. * 2. subjects who are able to complete the study in accordance with the requirements of the protocol. * 3. visiting subjects (including partners) who are willing to comply with the study provisions agree to have no pregnancy plans and no donor sperm plans throughout the trial and for 6 months after dosing, and to voluntarily use effective contraception, as described in appendix 4. * 4. subjects with bmi between 18 and 28 kg/m2 (both inclusive) and body weight between 55 and 85 kg (both inclusive). * 5. healthy chinese male subjects between the ages of 18 and 55 years (both inclusive). * 6. subjects with normal or abnormal physical examinations without clinical significance. exclusion criteria: * 1. subjects who have clinically significant abnormalities in clinical laboratory tests. * 2. subjects with clinical significance of abnormal ecg, chest x-ray. * 3. subjects with history of hypertension. * 4. subject who are or had been suffering from malignant neoplasm; subject who are or had been suffering from inflammatory bowel disease. * 5. subjects who have an active infection within 2 months prior to screening, including acute and chronic infections as well as localized infections. * 6. subjects who have active tuberculosis. * 7. subjects who have been exposed to tb within 3 months prior to screening. * 8. subjects whose t-cell test for tuberculosis infection (t-spot.tb) results are positive. * 9. subjects who are positive for hbsag on the hepatitis b half test. * 10. subjects who have had a major injury or undergone previous surgical procedures or fracture within 4 weeks prior to enrollment. * 11. subjects who have taken any prescription medication within 28 days prior to screening. * 12. subjects who participate in another drug clinical trial within 3 months prior to enrollment. * 13. subjects who suffered an acute illness from the screening period until study drug administration. * 14. subjects who have received mepolizumab (or its biosimilar) within 6 months (or within 5 half-lives of the drug, whichever is longer) prior to screening. * 15. subjects who have received live vaccination during the study period within 12 weeks prior to study dosing. * 16. subjects who are suspected or confirmed to be allergic (allergic to multiple medications or foods). * 17. subjects who smoked more than 5 cigarettes per day in the 3 months prior to screening. * 18. subjects who have taken any alcohol-containing product within 24h prior to study dosing. * 19. subjects who have donated blood or lost a significant amount of blood (\> 450 ml) within 3 months prior to study drug administration. * 20. subjects with a positive urine drug screening. * 21. subject who is deemed unsuitable for enrollment by the investigator.